Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Research

Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs

Michael L. Jackson1Comments to Author , Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 3

Figure 3. Predicted effects of extended Haemophilus influenzae type b (Hib) vaccine shortage on the incidence of invasive Hib disease in the United States (A) and of switching from PRP-OMP to PRP-T vaccine in the Alaska Native population (B). See text for complete description of shortage scenarios. PRP-OMP, Hib polyribosylribitol phosphate polysaccharide conjugated to Neisseria meningitidis outer membrane protein; PRP-T, polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid.

Main Article

1Current affiliation: Group Health Research Institute, Seattle, Washington, USA.

Page created: December 21, 2011
Page updated: December 21, 2011
Page reviewed: December 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external